MarketCap
Facebook
X
TelegramQuarterly report 2024-Q2
added 08-07-2024
Alimera Sciences Cost of Revenue 2011-2026 | ALIM
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Alimera Sciences
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10.8 M | 7.98 M | 7.03 M | 6.94 M | 6.63 M | 4.31 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 10.8 M | 4.31 M | 7.29 M |
Quarterly Cost of Revenue Alimera Sciences
| 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.83 M | 3.35 M | - | 2.42 M | 2.03 M | - | 2.01 M | 2.17 M | 1.68 M | - | 1.69 M | 1.81 M | 1.56 M | - | 1.54 M | 1.48 M | 1.93 M | - | 1.58 M | 1.17 M | 1.6 M | - | 965 K | 913 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.83 M | 913 K | 1.87 M |
Cost of Revenue of other stocks in the Drug manufacturers industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Adamis Pharmaceuticals Corporation
ADMP
|
6.19 M | - | 0.86 % | $ 117 M |  USA |
 |
Aerie Pharmaceuticals
AERI
|
26.8 M | - | - | $ 754 M | USA |
 |
Canopy Growth Corporation
CGC
|
189 M | $ 1.2 | 1.27 % | $ 129 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
6.21 M | - | 7.5 % | $ 6.35 M | USA |
 |
Agile Therapeutics
AGRX
|
8.98 M | - | 10.11 % | $ 58.2 M | USA |
 |
Catalent
CTLT
|
3.43 B | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
1.72 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
85.5 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
946 M | - | - | $ 28.9 M |  Irlanda |
 |
Emergent BioSolutions
EBS
|
705 M | $ 13.92 | 5.86 % | $ 713 M | USA |
 |
OrganiGram Holdings
OGI
|
104 M | $ 1.69 | 0.9 % | $ 402 M | Canada |
 |
Athenex
ATNX
|
76.1 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
15.3 M | $ 21.48 | -0.12 % | $ 2.04 B |  France |
 |
Evolus
EOLS
|
84 M | $ 5.72 | -3.3 % | $ 355 M | USA |
 |
Harrow Health
HROW
|
39.6 M | $ 50.79 | -5.07 % | $ 1.66 B | USA |
 |
China Pharma Holdings
CPHI
|
6.51 M | $ 1.38 | 9.13 % | $ 24.1 M |  China |
 |
Sundial Growers
SNDL
|
56.1 M | $ 1.66 | -1.19 % | $ 3.37 M | Canada |
 |
Jupiter Wellness
JUPW
|
3.15 M | - | - | $ 33.6 M | USA |
 |
Lannett Company
LCI
|
294 M | - | 1.15 % | $ 7.11 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
6.59 M | $ 5.14 | 8.9 % | $ 72.3 M | USA |
 |
Organogenesis Holdings
ORGO
|
116 M | $ 4.32 | -0.92 % | $ 569 M | USA |
 |
Pacira BioSciences
PCRX
|
170 M | $ 26.13 | 3.24 % | $ 1.21 B | USA |
 |
PetIQ
PETQ
|
849 M | - | 1.64 % | $ 400 M | USA |
 |
Recro Pharma
REPH
|
76.5 M | - | -4.76 % | $ 65.3 M | USA |
 |
Perrigo Company plc
PRGO
|
2.83 B | $ 14.7 | -0.47 % | $ 2.02 B | USA |
 |
ProPhase Labs
PRPH
|
52 M | - | - | $ 5.07 M | USA |
 |
Rockwell Medical
RMTI
|
74.9 M | $ 0.95 | 2.85 % | $ 22.2 M | USA |
 |
Radius Health
RDUS
|
18.4 M | - | - | $ 1.42 B | USA |
 |
Relmada Therapeutics
RLMD
|
4.04 K | $ 4.3 | 5.39 % | $ 129 M | USA |
 |
OptiNose
OPTN
|
8.63 M | - | - | $ 1.08 B | USA |
 |
Assertio Holdings
ASRT
|
27 M | $ 9.35 | -1.86 % | $ 664 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
8.82 M | $ 3.8 | - | $ 4.72 M | USA |
 |
PLx Pharma
PLXP
|
4.8 M | - | -27.8 % | $ 2.56 M | USA |
 |
SCYNEXIS
SCYX
|
15.4 M | $ 0.64 | -0.12 % | $ 30.6 M | USA |
 |
Tilray
TLRY
|
480 M | $ 8.95 | -3.35 % | $ 5.53 B | Canada |
 |
Veru
VERU
|
11 M | $ 2.34 | 0.43 % | $ 316 M | USA |
 |
TherapeuticsMD
TXMD
|
1.4 M | $ 2.0 | -2.0 % | $ 20.9 M | USA |
 |
Viatris
VTRS
|
9.77 B | $ 12.42 | 0.12 % | $ 15.1 B | USA |
 |
cbdMD
YCBD
|
7.49 M | $ 1.11 | -3.91 % | $ 4.79 M | USA |
 |
Zomedica Corp.
ZOM
|
7.87 M | - | -0.21 % | $ 98 M | USA |